HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use PARICALCITOL INJECTION safely and effectively. See full prescribing information for PARICALCITOL INJECTION.
PARICALCITOL injection, for intravenous use
Initial U.S. Approval: 1998
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
Paricalcitol Injection is a vitamin D2 analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis (1).
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Paricalcitol Injection is available as follows (3):
WARNINGS AND PRECAUTIONS
The most common adverse reactions (> 5% and more frequent than placebo) are nausea, vomiting, and edema (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.